skip to main
|
skip to sidebar
Blog Archives: Nov 2004 - present
Special items: Ovarian Cancer and Us blog best viewed in Firefox
Conclusion:
There should be a greater commitment by reimbursement agencies to a fair and transparent decisionmaking process with appropriate community input. Criteria should be developed to validate surrogate
markers for rare diseases. It should also be acknowledged that the traditional measures of benefit in
economic studies do not incorporate all elements of social value. The need should be recognized to balance equity with an efficient use of resources.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.